This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 3 of 53 for:    gastroparesis | Recruiting, Not yet recruiting, Available Studies

Study of Promethazine for Treatment of Diabetic Gastroparesis

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Dartmouth-Hitchcock Medical Center
American College of Gastroenterology
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center Identifier:
First received: May 1, 2014
Last updated: May 10, 2017
Last verified: May 2017
Adult diabetic patients (ages 18-65) with gastric emptying scintigraphy-confirmed delayed gastric emptying will be recruited to participate in the study. Using double-blinded methodology, study participants will be randomly assigned to one of two treatment arms: promethazine 12.5 mg three times daily for 28 days or placebo three times daily for 28 days. The primary outcome will be the change in gastroparesis symptom severity, as measured by the Gastroparesis Cardinal Symptom Index (GCSI) at four weeks compared to baseline. Participants will be seen for a clinic evaluation at weeks 0, 2 and 4, during which symptom scores, adverse events and treatment compliance will be assessed. It is hypothesized promethazine treatment will be superior to placebo in improving symptoms of gastroparesis.

Condition Intervention Phase
Diabetic Gastroparesis Drug: Promethazine Drug: Sugar pill Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.

Resource links provided by NLM:

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Change in patient-reported symptoms as measured by the Gastroparesis Cardinal Symptom Index score (GCSI, 14) from week 0 to week 4. [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Occurrence of adverse events [ Time Frame: 4 weeks ]
  • Use of rescue medication [ Time Frame: 4 weeks ]
    Frequency of use of the "rescue medication" meclizine

  • The impact on work activity as measured by the Work Productivity and Activity Impairment Questionnaire. (WPAI). [ Time Frame: 4 weeks ]

Estimated Enrollment: 24
Actual Study Start Date: July 2014
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Promethazine
Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
Drug: Promethazine
Other Name: Phenergan
Placebo Comparator: Sugar Pill
Placebo P.O. t.i.d. for 4 weeks
Drug: Sugar pill
Other Name: Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • adult patients 18-65 years of age
  • clinical diagnosis of diabetic gastroparesis.
  • EGD without evidence of gastric outlet obstruction within the past five years
  • gastric emptying scintigraphy test demonstrating >10% solid food retention at 4 hours within the past three years.

Exclusion Criteria:

  • the inability or unwillingness to provide informed consent
  • currently pregnant or breast feeding
  • prior placement of a gastric stimulator
  • pyloric botulinum toxin injection within the past 12 months
  • prior gastric surgery
  • history of a connective tissue disorder
  • use of narcotic medication within the past four weeks
  • hemoglobin A1C >12 mg/dL within the past 3 months
  • current or recent (within past 4 weeks) use of promethazine, metoclopramide or domperidone
  • hypersensitivity or prior adverse reaction to promethazine
  • concomitant use of phenothiazines (i.e. prochlorperazine, chlorpromazine) or other agents likely to increase extrapyramidal reactions
  • concomitant use of tiotropium or ipratropium
  • narrow angle glaucoma
  • urinary retention
  • Parkinson's disease
  • significant psychiatric disease
  • history of seizure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02130622

Contact: Jessica I Chevalier 603-653-9033

United States, New Hampshire
Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Jessica I. Chevalier    603-653-9033   
Contact: Anna M Haron    603-653-3667   
Principal Investigator: Brian E Lacy, MD, PhD         
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
American College of Gastroenterology
Principal Investigator: Brian E. Lacy, MD Dartmouth-Hitchcock Medical Center
  More Information


Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT02130622     History of Changes
Other Study ID Numbers: D14076
Study First Received: May 1, 2014
Last Updated: May 10, 2017

Keywords provided by Dartmouth-Hitchcock Medical Center:
Diabetic Gastroparesis

Additional relevant MeSH terms:
Stomach Diseases
Gastrointestinal Diseases
Digestive System Diseases
Neurologic Manifestations
Signs and Symptoms
Dermatologic Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Allergic Agents
Anesthetics, Local
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Autonomic Agents
Gastrointestinal Agents
Hypnotics and Sedatives processed this record on August 18, 2017